Vertex Pharmaceuticals will pay $245 million to acquire biotechnology company Exonics and extend its agreement with CRISPR Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Boston-based Vertex has secured an exclusive discovery and development deal with CRISPR Therapeutics, which it will use along with resources from Exonics to develop independent DMD products and continue research on DM1 treatments.
Vertex Pharmaceuticals will pay $420m to acquire biotechnology company Exonics and extend its agreement with CRISPR Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Boston-based Vertex has secured an exclusive discovery and development deal with CRISPR Therapeutics, which it will use along with resources from Exonics to develop independent DMD products and continue research on DM1 treatments.